Printer Friendly
The Free Library
5,670,285 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cell Bio-Systems Approves Design Enhancement for 60cc Syringe Hub Adaptor.


Business Editors/Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--June 1, 2004

Cell Bio-Systems, Inc. (Pink Sheets:CBSI CBSI CUNA Brokerage Services, Inc.
CBSI Cambodian Buddhist Society, Inc. (Silver Springs, Maryland)
CBSI Certified Bridge Safety Inspector
CBSI Custom Business Solutions, Inc.
), a biotechnology company seeking to manufacture and distribute patented, disposable technologies for cosmetic surgery cosmetic surgery, plastic surgery for cosmetic purposes, such as the improvement of the appearance of the face by removing wrinkles or reshaping the nose.  and other living tissue procedures, announced today that it has completed a design enhancement for its 60cc syringe hub adaptor. The 60cc hub adapter is the patented connection system that seals larger diameter cannulas, mostly used to extract fat tissue for re-injection, to a 60cc syringe.

The design enhancement to this patented, disposable device consists of an over-mold, a rubber-like piece molded to the main hub to compensate for variations in syringe diameters. The over-mold will eliminate problems commonly associated with tolerance variations in the syringe molds when used with current re-useable devices. These variations may cause the hub to either be too tight or too loose on the syringe.

"The design enhancement was completed just in time to be incorporated into our first set of production tools, thereby saving CBSI both time and money as we avoid having to create a complete new tooling group to accommodate the improvement," said Marc Pilkington, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Cell Bio-Systems. "Our design team's attention to detail has resulted in yet another of the many improvements that set apart CBSI's device technology."

Cell Bio-Systems recently announced the completion of its first set of production tools for the manufacture of the company's flagship instrument, the Super Luer, a patented connection system and the centerpiece component for the company's bio-device kits utilized in procedures ranging from liposuction Liposuction Definition

Liposuction, also known as lipoplasty or suction-assisted lipectomy, is cosmetic surgery performed to remove unwanted deposits of fat from under the skin.
 and fat re-injections to gene therapy technologies and stem cell stem cell

In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult.
 research.

The Super Luer will be adapted to manufacture the first affordable, disposable cannula cannula /can·nu·la/ (kan´u-lah) a tube for insertion into a vessel, duct, or cavity; during insertion its lumen is usually occupied by a trocar.

can·nu·la or can·u·la
n. pl.
. A cannula is an enclosed tubular device, currently made from stainless steel stainless steel: see steel.
stainless steel

Any of a family of alloy steels usually containing 10–30% chromium. The presence of chromium, together with low carbon content, gives remarkable resistance to corrosion and heat.
, that looks much like a large needle and has been popularized by its use to insert or extract tissue during liposuction and collagen implant procedures. Though re-sterilized, steel cannulas are reused in hundreds of procedures, typically for as long as two years or more. Despite safety concerns and complications regularly ascribed to steel cannulas, no comparable, disposable device currently exists.

About Cell Bio-Systems

Based in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation).
San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951.
, Cell Bio-Systems is the exclusive licensee of two patented syringe connection products that it plans to adapt as disposable devices for liposuction and other Living Tissue Management(TM) procedures. The company is developing an affordable, disposable product Disposable products are items that are not intended by the manufacturer to be reused more than once or a few times as compared to more permanent serviceable and reusable items. Some products that have disposable versions are:
  • diapers
  • cigarette lighters
  • flatware
 line that will fill this void in the cosmetic surgery and living tissue marketplace. The company's patented, groundbreaking technology will increase patient safety and enhance procedural outcomes. Most notably, Cell Bio-Systems devices can be adapted for a variety of procedures, ranging from fat transfers to biopsies to stem cell research. The company ultimately will develop a complete living tissue management system. CBSI shareholders are encouraged to visit www.cellbiosystems.com and to register on the "Investor Relations Investor relations

The process by which the corporation communicates with its investors.
" page to receive ongoing CBSI news updates.

Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements'' as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. CBSI disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, and changes in our business strategies.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 1, 2004
Words:640
Previous Article:The Phoenix Group Corporation Acquires Lighting Science, Inc.
Next Article:Verific to Exhibit at 41st Design Automation Conference; First-Time Exhibitor to Demonstrate HDL Component Software.



Related Articles
Repro-Med Systems Awarded Government Contract.
Tech Science Press launches two new journals.(Brief Article)
Cell Bio-Systems CEO Speaks to WallStreetReporter.
Cell Bio-Systems Adds John Johnson to Board of Directors.
Cell Bio-Systems Approves Prototype Design of Liposuction Handle.
Cell Bio-Systems Completes Prototype Design of Super Luer Tissue Transfer Device.
All fluid' needles.(Product SPOTLIGHT)
HTS Biosystems and Dyax Corporation Enter Collaboration Agreement.
Invitrogen Corporation Expands Proteomics Capabilities with Launch of Mass Spectrometry Solutions and Co-Marketing Agreement with Applied Biosystems.
Rapid genome sequencing of RNA viruses.(DISPATCHES)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles